ISPOR BOARD OF DIRECTORS ELECTION 2015

Published Mar 4, 2015
Dear Colleagues: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a member-driven organization led by a diverse Board of Directors and professional staff who work collaboratively to ensure the organization is strategically positioned and effectively serving its membership. As such, ISPOR members are encouraged to participate in the election for the 2015-2016 ISPOR Board of Directors and help shape the future of ISPOR. ABOUT THE CANDIDATES: The ISPOR Board of Directors consists of the Officers (President, President-Elect, Immediate Past President), and seven Directors. The Board term of office for the President is one year as President-Elect, one year as a President, and one year as a Past President. After an extensive review and deliberation of more than 60 nominees, the ISPOR Nominations Committee has recommended the following candidates for the 2015-16 Board election. (All ISPOR members are strongly encouraged to review the candidate backgrounds and vote in this election. To read the candidate's biographical summary and their ISPOR vision statement go to: Candidate biographical summaries & ISPOR vision statements.) President-elect Lou Garrison, PhD (USA) Maarten J. IJzerman, PhD (The Netherlands) Director (Position 1) Diego Rosselli, MD, MED, MHP (Colombia) Manuel Espinoza S., MD, MSc, PhD (Chile) Director (Position 2) Dana Goldman, PhD (USA) Todd Lee, PharmD, PhD (USA) Director (Position 3) Nancy Devlin, PhD (UK) Mitchell Higashi, PhD (USA) TO VOTE: Access the ballot clicking on the “VOTE NOW!” icon below. You will be directed to enter your ISPOR member email address and member ID. All ballots are verified and tabulated by an independent agency.

YOU MUST VOTE BY MAY 1, 2015

Sincerely, William H. Crown, PhD 2014-2015 Board of Directors Nominations Committee Chair & 2014-2015 Past-President Vote Now!

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×